Yuan-Hui Jia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuan-Hui Jia has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Meng-Lin Dong
College of Chemistry, Chemical Engineering, and Materials Science, Soochow University, Suzhou 215123, China, China
2 shared publications - Wen-Hua Zhang
College of Chemistry, Chemical Engineering and Materials Science, Soochow University, Suzhou 215123, China
2 shared publications - Ye Ning
College of Chemistry, Chemical Engineering, and Materials Science, Soochow University, Suzhou 215123, China, China
2 shared publications - Yiming Mao
Department of Thoracic Surgery, Suzhou Kowloon Hospital Shanghai Jiao Tong University School of Medicine, China
2 shared publications - Wenqiang Lu
Department of Thoracic Surgery, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou, China
1 shared publication - Wenqiang Lu
Department of Thoracic Surgery, Suzhou Kowloon Hospital, Shanghai Jiao Tong University School of Medicine, Suzhou 215021, China
1 shared publication
Latest Publications
- Open Access
A Nonanuclear Pd-Based Coordination Cage Featuring Ni-Chelated Porphyrin Ligand for Cancer Therapy via Combination of Chemodynamic and Photodynamic Modalities
Reactive oxygen species (ROS)-mediated cancer therapy has attracted extensive attention due to its high spatiotemporal selectivity and minimal side effects. Herein, we report a nonanuclear Pd-based coordination cage of Pd6-TMPP(Ni), constructed from Ni-chelated TMPP(Ni) as the metalloligand and Pd2+ ions (H2TMPP = meso-tetrakis (6-methylpyridin-3-yl) porphyrin). Pd6-TMPP(Ni) integrates dual ROS-generation for cancer therapy, viz., hydroxyl radical (•OH) production and photoinduced singlet oxygen (1O2) generation. In vitro cytotoxicity assays against cancer cell lines NCI-H82 (lung cancer), A549 (lung cancer), KYSE-510 (esophageal cancer), and Te-1 (esophageal cancer) reveal its potent dark toxicity (IC50: 1.9–2.1 μmol L−1) and phototoxicity (IC50: 0.8–1.5 μmol L−1), which is attributed to enhanced intracellular ROS accumulation. This work develops a versatile therapeutic platform that harnesses Ni-induced •OH for chemodynamic therapy (CDT) and porphyrin-generated 1O2 for photodynamic therapy (PDT), thereby mitigating the oxygen dependence of conventional PDT.
Open AccessA Nonanuclear Pd-Based Coordination Cage Featuring Ni-Chelated Porphyrin Ligand for Cancer Therapy via Combination of Chemodynamic and Photodynamic Modalities
Reactive oxygen species (ROS)-mediated cancer therapy has attracted extensive attention due to its high spatiotemporal selectivity and minimal side effects. Herein, we report a nonanuclear Pd-based coordination cage of Pd6-TMPP(Ni), constructed from Ni-chelated TMPP(Ni) as the metalloligand and Pd2+ ions (H2TMPP = meso-tetrakis (6-methylpyridin-3-yl) porphyrin). Pd6-TMPP(Ni) integrates dual ROS-generation for cancer therapy, viz., hydroxyl radical (•OH) production and photoinduced singlet oxygen (1O2) generation. In vitro cytotoxicity assays against cancer cell lines NCI-H82 (lung cancer), A549 (lung cancer), KYSE-510 (esophageal cancer), and Te-1 (esophageal cancer) reveal its potent dark toxicity (IC50: 1.9–2.1 μmol L−1) and phototoxicity (IC50: 0.8–1.5 μmol L−1), which is attributed to enhanced intracellular ROS accumulation. This work develops a versatile therapeutic platform that harnesses Ni-induced •OH for chemodynamic therapy (CDT) and porphyrin-generated 1O2 for photodynamic therapy (PDT), thereby mitigating the oxygen dependence of conventional PDT.
- Open Access
- 21 April 2026
- Published by MDPI AG in Preprints.org
A Nonanuclear Pd-Based Coordination Cage Featuring Ni-Chelated Porphyrin Ligand for Cancer Therapy via Combination of Chemodynamic and Photodynamic Modalities
Reactive oxygen species (ROS)-mediated cancer therapy has attracted extensive attention due to its high spatiotemporal selectivity and minimum side-effects. Herein, we report a nonanuclear Pd-based coordination cage of Pd6-TMPP(Ni), constructed from Ni-chelated TMPP(Ni) as the metalloligand and Pd2+ ions (H2TMPP = meso-tetrakis (6-methylpyridin-3-yl) porphyrin). Pd6-TMPP(Ni) integrates dual ROS-generation for cancer therapy, viz., hydroxyl radical (•OH) production and photoinduced singlet oxygen (1O2) generation. In vitro cytotoxicity assays against cancer cell lines NCI-H82 (lung cancer), A549 (lung cancer), KYSE-510 (esophageal cancer), and Te-1 (esophageal cancer), reveal its potent dark toxicity (IC₅₀: 1.867–2.107 μmol L−1) and phototoxicity (IC₅₀: 0.835–1.528 μmol L−1), which is attributed to enhanced intracellular ROS accumulation. This work develops a versatile therapeutic platform that harnesses Ni-induced •OH for chemodynamic therapy (CDT) and porphyrin-generated ¹O₂ for photodynamic therapy (PDT), thereby mitigating the oxygen dependence of conventional PDT.
- 21 April 2026
- Published by MDPI AG in Preprints.org
Open AccessA Nonanuclear Pd-Based Coordination Cage Featuring Ni-Chelated Porphyrin Ligand for Cancer Therapy via Combination of Chemodynamic and Photodynamic Modalities
Reactive oxygen species (ROS)-mediated cancer therapy has attracted extensive attention due to its high spatiotemporal selectivity and minimum side-effects. Herein, we report a nonanuclear Pd-based coordination cage of Pd6-TMPP(Ni), constructed from Ni-chelated TMPP(Ni) as the metalloligand and Pd2+ ions (H2TMPP = meso-tetrakis (6-methylpyridin-3-yl) porphyrin). Pd6-TMPP(Ni) integrates dual ROS-generation for cancer therapy, viz., hydroxyl radical (•OH) production and photoinduced singlet oxygen (1O2) generation. In vitro cytotoxicity assays against cancer cell lines NCI-H82 (lung cancer), A549 (lung cancer), KYSE-510 (esophageal cancer), and Te-1 (esophageal cancer), reveal its potent dark toxicity (IC₅₀: 1.867–2.107 μmol L−1) and phototoxicity (IC₅₀: 0.835–1.528 μmol L−1), which is attributed to enhanced intracellular ROS accumulation. This work develops a versatile therapeutic platform that harnesses Ni-induced •OH for chemodynamic therapy (CDT) and porphyrin-generated ¹O₂ for photodynamic therapy (PDT), thereby mitigating the oxygen dependence of conventional PDT.